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The recent successes in the immunotherapy field demon-
strate that a successful immune response to cancer can
lead to meaningful anti-tumor responses. Antibodies
blocking immune checkpoint molecules (e.g. CTLA4,
and PD-1) lead to effective T cell responses especially in
tumors that are immune active.
Immune cells that have not received as much attention
in cancer immunotherapy are neutrophils. Neutrophils
are the most abundant white blood cells, which protect
us from microbial infections. They are the first line of
innate defense: they arrive early on in the course of infec-
tion, phagocytose, and release the content of their gran-
ules, including reactive oxygen species and enzymes.
Neutrophils also communicate with other immune cells,
such as macrophages, dendritic cells, and T cells, by
releasing cytokines and chemokines, leading to an orche-
strated innate and adaptive immune response.
There has long been a call for a targeted recruitment
of these professional killers to fight cancer. However, an
approach that mediates the recruitment of neutrophils
has to lead to acute as opposed to chronic inflammation
to overcome the suppressive environment that tumors
surround themselves with.
We have developed a novel immunotherapy platform
technology, termed mAbXcite, which directs and acti-
vates neutrophils to initiate a robust innate and adaptive
immune response to kill cancer cells in a targeted man-
ner. The targeting is achieved by using monoclonal anti-
bodies that are chemically linked to beta-1, 6-glucan, a
saccharide found on the cell walls of fungal species
which recruits and activates neutrophils. The resulting
mAb construct attracts mediators of acute inflammation,
notably neutrophils, which are followed by macrophages
and T cells.
We have shown that this platform leads to stasis and
regressions in tumor models that are resistant to mono-
clonal antibodies that target peripheral cancer antigens,
including validated antibodies (e.g. trastuzumab and
cetuximab) and experimental mouse antibodies.
Here, we will show that the platform can be applied to
antibodies that target the tumor microenvironment
resulting in greater efficacy and changes in infiltrating
immune cells.
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